Corvus Pharmaceuticals, Inc.
CRVS
$13.33
-$0.60-4.31%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -17.96M | -13.69M | -12.32M | -10.16M | -8.00M |
| Total Depreciation and Amortization | 34.00K | 29.00K | 26.00K | 28.00K | 29.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.50M | 3.23M | 2.02M | 1.11M | -701.00K |
| Change in Net Operating Assets | -976.00K | 57.00K | 1.08M | -550.00K | 2.89M |
| Cash from Operations | -15.40M | -10.37M | -9.19M | -9.57M | -5.78M |
| Capital Expenditure | -582.00K | -91.00K | -25.00K | 0.00 | -113.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -5.38M | -144.76M | 10.91M | -2.62M | -20.19M |
| Cash from Investing | -5.97M | -144.85M | 10.88M | -2.62M | -20.30M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 166.00K | 190.75M | 20.00K | 360.00K | 35.77M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 166.00K | 190.75M | 20.00K | 360.00K | 35.77M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -21.20M | 35.53M | 1.71M | -11.82M | 9.69M |